色甘酸和奈多罗米对哮喘儿童的治疗

Cromolyn and nedocromil therapy of asthmatic children.

作者信息

Furukawa C T

机构信息

University of Washington, School of Medicine, Seattle.

出版信息

Allergy Proc. 1989 May-Jun;10(3):189-90. doi: 10.2500/108854189778960063.

DOI:10.2500/108854189778960063

PMID:2548926

Abstract

Controlled studies of cromolyn treatment of asthmatic children have revealed benefits beyond the incredible safety of the drug. It is now recognized that the patient with asthma will have decreased asthma and less bronchial hyperreactivity when treated for more than two months with cromolyn. Also, the reduced sensitivity of beta-receptors with chronic use of beta adrenergic drugs is abated with concomitant cromolyn use. It is hoped that the studies with nedocromil will reveal additional benefits with this class of antiasthmatic medication.

摘要

对色甘酸钠治疗哮喘儿童的对照研究表明，该药除了具有令人难以置信的安全性外，还有其他益处。现在人们认识到，哮喘患者使用色甘酸钠治疗两个多月后，哮喘症状会减轻，支气管高反应性也会降低。此外，长期使用β-肾上腺素能药物导致的β-受体敏感性降低，在同时使用色甘酸钠时会得到缓解。人们希望对奈多罗米的研究能揭示这类抗哮喘药物的更多益处。